EC updates on Bayer divestments regarding Monsanto merger

30 April 2018
mergers-acquisitions-big

The European Commission has conditionally approved under the EU Merger Regulation the acquisition of parts of Bayer's (BAYN: DE) Crop Science business by fellow Germany-based BASF (BAS: DE), which is the world’s largest chemical company.

This transaction is related to the $66 billion Bayer takeover of USA-based Monsanto (NYSE: MON), agreed between the companies in September 2016, and previously announced merger divestment commitments. The merger will create the world's largest integrated pesticides and seeds company.

Bayer has already committed to divest an extensive remedy package worth well over 6 billion euros ($7.26 billion to address the competition concerns on overlaps between Bayer and Monsanto in seeds, pesticides and digital agriculture. The Commission concluded that this divestment package would enable a suitable buyer to sustainably replace Bayer's competitive effect in these markets and continue to innovate, for the benefit of European farmers and consumers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical